Drug Profile


Alternative Names: MEG

Latest Information Update: 13 Sep 2007

Price : $50

At a glance

  • Originator Nonindustrial source
  • Developer Inotek Pharmaceuticals; Nonindustrial source
  • Class Guanidines; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Nitric oxide synthase type II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Inflammation; Rheumatoid arthritis; Shock; Systemic inflammatory response syndrome

Most Recent Events

  • 17 Apr 2002 No development reported - Preclinical for Systemic inflammatory response syndrome in USA (unspecified route)
  • 17 Apr 2002 No development reported - Preclinical for Shock in USA (unspecified route)
  • 17 Apr 2002 No development reported - Preclinical for Rheumatoid arthritis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top